Dianthus Therapeutics, Inc.
DNTH
$78.86
-$0.04-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 284.00K | 396.00K | 193.00K | 1.16M | 1.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 284.00K | 396.00K | 193.00K | 1.16M | 1.33M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 284.00K | 396.00K | 193.00K | 1.16M | 1.33M |
| SG&A Expenses | 9.91M | 8.20M | 8.87M | 7.34M | 6.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.83M | 40.68M | 35.12M | 34.34M | 33.24M |
| Operating Income | -69.54M | -40.29M | -34.93M | -33.18M | -31.92M |
| Income Before Tax | -64.43M | -36.77M | -31.63M | -29.51M | -28.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.43M | -36.77M | -31.63M | -29.51M | -28.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.43M | -36.77M | -31.63M | -29.51M | -28.44M |
| EBIT | -69.54M | -40.29M | -34.93M | -33.18M | -31.92M |
| EBITDA | -69.51M | -40.26M | -34.90M | -33.15M | -31.89M |
| EPS Basic | -1.43 | -0.97 | -0.88 | -0.82 | -0.81 |
| Normalized Basic EPS | -0.91 | -0.65 | -0.57 | -0.55 | -0.55 |
| EPS Diluted | -1.43 | -0.97 | -0.88 | -0.82 | -0.81 |
| Normalized Diluted EPS | -0.91 | -0.65 | -0.57 | -0.55 | -0.55 |
| Average Basic Shares Outstanding | 44.97M | 37.79M | 35.82M | 35.79M | 35.03M |
| Average Diluted Shares Outstanding | 44.97M | 37.79M | 35.82M | 35.79M | 35.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |